Hudson Valley Cardiovascular Practice, PC
Poughkeepsie, New York 12601
3 studies enrolling now · 12 studies all time
What they study most
Acute Coronary Syndrome, Acute Coronary Syndromes, Atherosclerotic Cardiovascular Disease, Bradycardia, Cardiovascular Disease, Coronary Artery Disease, Coronary Revascularization, Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure With Mildly Reduced Ejection Fraction
Studies at this site
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention — Recruiting now
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
- EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction — Running, not enrolling
- Hemodynamic-GUIDEd Management of Heart Failure — Completed
- MitraClip EXPAND G4 Study — Running, not enrolling
- Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial — Running, not enrolling
- SJM Brady MRI Post Approval Study — Stopped early
- A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
- The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
- The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early